Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial - Miller, V A; Hirsh, V; Cadranel, J (Lancet Oncol, 2012)
et al.